TITLE

β2 Adrenergic agonist therapy may enhance alveolar epithelial repair in patients with acute lung injury

AUTHOR(S)
Matthay, Michael A.; Lee, Joyce
PUB. DATE
March 2008
SOURCE
Thorax;Mar2008, Vol. 63 Issue 3, p189
SOURCE TYPE
Academic Journal
DOC. TYPE
Editorial
ABSTRACT
The authors reflect on a study that examines the hypothesis that Î’2 adrenergic agonist therapy might enhance alveolar epithelial repair in patients with acute lung injury. They state that the researchers provide suggestive evidence that Î’2 adrenergic therapy might be able to enhance alveolar lung epithelial repair. Furthermore, they suggest that the researchers should be commended for a refined translational study that tests a novel mechanism.
ACCESSION #
31505920

 

Related Articles

  • In vivo and in vitro effects of salbutamol on alveolar epithelial repair in acute lung injury. Perkins, G. D.; Gao, F.; Thickett, D. R. // Thorax;Mar2008, Vol. 63 Issue 3, p215 

    Background: Acute lung injury is an important cause of respiratory failure in the critically ill patient. It is caused by damage to the alveolar barrier with subsequent alveolar flooding leading to the development of refractory hypoxaemia. β Agonists stimulate alveolar fluid clearance in...

  • IPRATROPIUM OR LABA IN COPD?  // Pulse;8/10/2006, Vol. 66 Issue 31, p26 

    The article focuses on the relative efficacy and safety of regular long-term use of ipratorium bromide and long-acting beta-2 agonists (LABA) in patients with stable chronic obstructive pulmonary disease. The two medications have different mechanism of action and theoretically could have an...

  • A Benefit-Risk Assessment of Inhaled Long-Acting β2-Agonists in the Management of Obstructive Pulmonary Disease. Sovani, Milind P; Whale, Christopher I.; Tattersfield, Anne. E // Drug Safety;2004, Vol. 27 Issue 10, p689 

    The two inhaled long-acting β2-adrenoceptor agonists, salmeterol and formoterol, have been studied extensively since their introduction in the early 1990s. In this review we consider the evidence for their efficacy and safety in adults with asthma and chronic obstructive pulmonary disease...

  • Benefit-Risk Assessment of Long-Acting β2-Agonists in Asthma. Jackson, Catherine M.; Lipworth, Brian // Drug Safety;2004, Vol. 27 Issue 4, p243 

    The use of a regular long-acting β2-adrenoceptor agonists β2-agonists; LABA) is now established in asthma guidelines as the preferred option for second-line controller therapy in addition to inhaled corticosteroids. This has been driven by data showing beneficial effects of LABAs on...

  • Budesonide/Formoterol: A Viewpoint by Paul W. Jones. Jones, Paul W. // Drugs;2004, Vol. 64 Issue 4, p444 

    Budesonide/formoterol is a fixed-dose combination of the corticosteroid budesonide and formoterol, a long-acting J32-agonist, inhaled as a dry powder. Current guidelines for chronic obstructive pulmonary disease (COPD) recommend a long-acting p2-agonist for patients whose symptoms are not...

  • Budesonide/Formoterol: A Viewpoint by Michael Roth1,2. Michael Roth, Paul W. // Drugs;2004, Vol. 64 Issue 4, p443 

    This article presents views of the author on formoterol. Corticosteroids combined with long-acting J32-agonists, for example budesonide/formoterol, have been suggested for the treatment of inflammatory lung diseases, including asthma and chronic obstructive pulmonary disease (COPD). The...

  • Review: Regular inhaled short-acting β[sub2]-agonists improve lung function in stable chronic obstructive pulmonary disease.  // ACP Journal Club;Jan/Feb2004, Vol. 140 Issue 1, p12 

    This article focuses on a study regarding regular inhaled short acting β[sub2] agonists (ISABAs) for the management of stable chronic obstructive pulmonary disease (COPD), published in the 2003 issue of the journal "Thorax." For this study the researchers selected studies if they were...

  • Review: Regular inhaled short-acting β[sub2]-agonists improve lung function in stable chronic obstructive pulmonary disease: COMMENTARY. Gibson, Peter G. // ACP Journal Club;Jan/Feb2004, Vol. 140 Issue 1, p12 

    This article focuses on a study regarding regular inhaled short acting β[sub2] agonists (ISABAs) for the management of stable chronic obstructive pulmonary disease (COPD), published in the 2003 issue of the journal "Thorax." COPD is defined as airflow limitation that is progressive, not fully...

  • Discussion.  // Respiratory Care;May2008, Vol. 53 Issue 5, p623 

    The article presents a discussion of the paper "Safety and Efficacy of β agonists" by James F. Donohue. Donohue says he would not use short-acting β agonists regularly in asthma or chronic obstructive pulmonary disease, because there's a lot of loss of bronchial protection. Meanwhile, he...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sign out of this library

Other Topics